UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-35238
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
70 St.
Stephen’s Green
Dublin 2, D02 E2X4, Ireland
011 353 1 772 2100
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Ordinary Shares, nominal value $0.0001 per share
(Title of each class of securities covered by this Form)
None
(Titles of all
other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the
box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
|
|
| Rule 12g-4(a)(1) |
|
☒ |
| Rule 12g-4(a)(2) |
|
☐ |
| Rule 12h-3(b)(1)(i) |
|
☒ |
| Rule 12h-3(b)(1)(ii) |
|
☐ |
| Rule 15d-6 |
|
☐ |
| Rule 15d-22(b) |
|
☐ |
Approximate number of holders of record as of the certification or notice date: One (1) holder
Effective as of October 6, 2023, Pillartree Limited, a wholly owned subsidiary of Amgen Inc. (“Amgen”), acquired Horizon Therapeutics plc
(“Horizon”) pursuant to a court-sanctioned scheme of arrangement under Irish law, resulting in Horizon becoming a wholly owned subsidiary of Amgen.
Pursuant to the requirements of the Securities Exchange Act of 1934, Horizon Therapeutics Public Limited Company has caused this
certification/notice to be signed on its behalf by the undersigned duly authorized person.
|
|
|
|
|
|
|
| Date: October 16, 2023 |
|
|
|
By: |
|
/s/ Sean Clayton |
|
|
|
|
Name: |
|
Sean Clayton |
|
|
|
|
Title: |
|
Executive Vice President, General Counsel |